Anticancer Research · 2018 · 11 citations · 14 references
MedicineOncologyPharmacotherapyMedical OncologyNeuro-oncologyOncology PharmacotherapyBrain TumorsCentral Nervous System Tumor PharmacotherapyGlioblastomaNeuro-oncology Clinical TrialsDeferred TreatmentGlioblastoma Clinical TrialsGlioblastoma Drug TherapyGlioblastoma Targeted TherapyGlioblastoma TrialsOverall Survival After RecurrenceRecurrenceTiming
BACKGROUND/AIM: In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). MATERIALS AND METHODS: This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months). RESULTS: The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318). CONCLUSION: Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma.
14
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Michael Weller, Martin J. van den Bent, Kirsten Hopkins et al. · The Lancet Oncology · 2014 · 755 citations · Full text
Medicine, Neurosurgery, Oncology +14